Compare FNUC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNUC | TCRX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 63.6M |
| IPO Year | 2021 | 2021 |
| Metric | FNUC | TCRX |
|---|---|---|
| Price | $2.44 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 300.4K | ★ 964.6K |
| Earning Date | 03-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $1.89 | $0.88 |
| 52 Week High | $2.82 | $2.57 |
| Indicator | FNUC | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 47.94 |
| Support Level | $2.26 | $0.90 |
| Resistance Level | $2.51 | $1.24 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 52.44 | 49.25 |
Frontier Nuclear and Minerals Inc is developing a U.S.-focused front-end nuclear fuel cycle company through a portfolio of U.S. uranium exploration and development projects in Wyoming, Colorado, and Utah, together with investments in next-generation uranium enrichment and small modular reactors. Frontier Nuclear is actively evaluating value-accretive investment opportunities in other sectors of the domestic U.S. nuclear fuel cycle. The group is developing a portfolio of critical minerals projects in America, Canada, and Namibia, including uranium, tantalum, cesium, and lithium. Its projects are Engo Valley, Pine Ridge, Shatford Lake, Snow Lake Lithium, and Tallahassee.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.